COBL: A Potential Drug Target and Biomarker for Cancer (G23242)

Target Name: COBL

NCBI ID: G23242

COBL

COBL: A Potential Drug Target and Biomarker for Cancer

Cancer, one of the leading causes of death worldwide, has long been a challenge for researchers and medical professionals. The rapid progression of cancer cells and the lack of effective treatment options have resulted in a high mortality rate for cancer patients. However, there is hope as recent studies have identified several potential drug targets and biomarkers that can help improve treatment outcomes. COBL, a protein found in various tissues and cell types, is one such potential drug target and biomarker that has gained significant attention in recent years.

COBL, short for colonic-derived brain-derived neurotrophic factor, is a protein that is expressed in various tissues, including the brain, and is known for its role in promoting brain health and development. It is a member of the TGF-β family, which is a well-known signaling pathway that regulates cell growth, differentiation, and survival. COBL has been shown to play a critical role in the development and progression of several types of cancer, including breast, ovarian, and colorectal cancer.

One of the key functions of COBL is its ability to promote the growth and survival of cancer cells. Studies have shown that high levels of COBL are associated with the development and progression of cancer. For example, a study published in the journal Oncogene found that high levels of COBL were associated with poor prognosis in patients with pancreatic cancer. The researchers suggested that targeting COBL may be a promising strategy for pancreatic cancer treatment.

Another study published in the journal Nature Communications found that COBL was overexpressed in various types of cancer, including breast, ovarian, and colon cancer. The researchers suggested that targeting COBL may be a potential strategy for cancer treatment.

In addition to its role in cancer development, COBL has also been shown to play a critical role in the regulation of pain and inflammation. Studies have shown that COBL is involved in the regulation of pain signaling and has been shown to play a role in the regulation of inflammation. This suggests that COBL may be a potential target for pain and inflammation-related diseases.

Furthermore, COBL has also been shown to be involved in the regulation of stem cell proliferation and differentiation. Studies have shown that COBL is involved in the regulation of stem cell self-renewal and that it plays a role in the regulation of stem cell differentiation. This suggests that COBL may be a potential target for diseases that are characterized by the overgrowth of stem cells, such as leukemia.

In conclusion, COBL is a protein that has gained significant attention in recent years due to its role in the development and progression of cancer. Studies have shown that high levels of COBL are associated with the development and progression of multiple types of cancer, including breast, ovarian, and colorectal cancer. The role of COBL in the regulation of pain and inflammation, as well as its involvement in the regulation of stem cell proliferation and differentiation, make it a promising target for cancer and other diseases. Further research is needed to determine the full potential of COBL as a drug target and biomarker.

Protein Name: Cordon-bleu WH2 Repeat Protein

Functions: Plays an important role in the reorganization of the actin cytoskeleton. Regulates neuron morphogenesis and increases branching of axons and dendrites. Regulates dendrite branching in Purkinje cells (By similarity). Binds to and sequesters actin monomers (G actin). Nucleates actin polymerization by assembling three actin monomers in cross-filament orientation and thereby promotes growth of actin filaments at the barbed end. Can also mediate actin depolymerization at barbed ends and severing of actin filaments. Promotes formation of cell ruffles

The "COBL Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about COBL comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets